Structure Therapeutics Phase 2 Obesity Data Shifts Focus To Phase 3 [Yahoo! Finance]
Structure Therapeutics Inc. (GPCR)
Company Research
Source: Yahoo! Finance
Structure Therapeutics (NasdaqGM:GPCR) reported positive topline Phase 2 results for its oral GLP-1 receptor agonist aleniglipron in obesity. The data indicate strong efficacy and favorable tolerability in adults with obesity or overweight with at least one co-morbidity. The company plans to advance aleniglipron into Phase 3 development based on these results. Structure Therapeutics focuses on oral small molecule drugs, and aleniglipron sits at the center of its efforts in metabolic disease. GLP-1 drugs have become a major focus in obesity treatment, and an oral option is of particular interest for patients and payers that prefer pills over injectables. This Phase 2 update places NasdaqGM:GPCR more firmly in the group of companies developing oral GLP-1 candidates. For investors, the move toward Phase 3 means the story shifts from early proof of concept to larger, longer and more expensive trials. Attention now turns to the eventual Phase 3 design, regulatory feedback, and how
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics (GPCR) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GPCR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
- Structure Therapeutics (GPCR) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
- Structure Therapeutics CEO on the company's oral GLP-1 opportunity [CNBC]CNBC
- Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III [Yahoo! Finance]Yahoo! Finance
GPCR
Sec Filings
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- GPCR's page on the SEC website